biostudies-literatureFinocchiaro CBiogen srl1783-1796https://www.ebi.ac.uk/biostudies/studies/S-EPMC12645145biostudies-literatureUnknown23(13)<h4>Background</h4>Disease-modifying therapies (DMTs) are aimed at controlling Multiple Sclerosis disease by modulating or suppressing the immune system. However, there is limited data on changes in immune cell subsets induced by these treatments.<h4>Objective</h4>To assess differences in myeloid, T-, and B-cell subsets in the peripheral blood of relapsing- remitting MS (RR-MS) patients treated with different DMTs.<h4>Methods</h4>This longitudinal study enrolled all RR-MS patients treated with cladribine (CLAD), dimethyl fumarate (DMF), and natalizumab (NTZ) between July 2022 and September 2022. All patients underwent blood sample collection with flow cytometry at baseline (T0; before starting treatment) and 24 ± 3 months after treatment initiation (T1).<h4>Results</h4>Forty-three RR-MS paCurrent neuropharmacology&lt;i&gt;In vivo&lt;/i&gt; Effects of Disease-modifying Therapies on Immunological Subsets in Patients with Relapsing-Remitting Multiple Sclerosis.PMC12645145BGT-11698Di Raimondo FChisari CGCorsale AMMarino SFinocchiaro CParrinello NLPalumbo GAZappia MLo Fermo SD'Amico ERomano APatti Ffalse&lt;i&gt;In vivo&lt;/i&gt; Effects of Disease-modifying Therapies on Immunological Subsets in Patients with Relapsing-Remitting Multiple Sclerosis.<h4>Background</h4>Disease-modifying therapies (DMTs) are aimed at controlling Multiple Sclerosis disease by modulating or suppressing the immune system. However, there is limited data on changes in immune cell subsets induced by these treatments.<h4>Objective</h4>To assess differences in myeloid, T-, and B-cell subsets in the peripheral blood of relapsing- remitting MS (RR-MS) patients treated with different DMTs.<h4>Methods</h4>This longitudinal study enrolled all RR-MS patients treated with cladribine (CLAD), dimethyl fumarate (DMF), and natalizumab (NTZ) between July 2022 and September 2022. All patients underwent blood sample collection with flow cytometry at baseline (T0; before starting treatment) and 24 ± 3 months after treatment initiation (T1).<h4>Results</h4>Forty-three RR-MS pa2025-01-01T00:00:00Z20252026-06-06T09:39:32.74Z2026-05-28T03:11:59.123ZS-EPMC126451454062175710.2174/011570159X360729250319064959